Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies.

Magdalena Komiazyk, Jaroslaw Walory, Jan Gawor, Iza Ksiazek, Robert Gromadka, Anna Baraniak
Author Information
  1. Magdalena Komiazyk: Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, 00-725 Warsaw, Poland. ORCID
  2. Jaroslaw Walory: Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, 00-725 Warsaw, Poland. ORCID
  3. Jan Gawor: DNA Sequencing and Synthesis Facility, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland. ORCID
  4. Iza Ksiazek: Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, 00-725 Warsaw, Poland.
  5. Robert Gromadka: DNA Sequencing and Synthesis Facility, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland. ORCID
  6. Anna Baraniak: Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, 00-725 Warsaw, Poland. ORCID

Abstract

The introduction of effective vaccines against SARS-CoV-2 is expected to prevent COVID-19. However, sporadic cases of infection in vaccinated persons have been reported. We describe a case of a double-dose vaccinated woman with COVID-19. All stages of infection were observed, from no identification of virus, then the start of the infection, a high viral load, coming out of viraemia, and finally no detection of the virus. Despite the high viral load, the woman demonstrated mild COVID-19 symptoms, manifested only by a sore throat. The antibody results showed that she produced both post-infectious and post-vaccination immune responses. Phylogenetic analysis of the obtained viral genome sequence indicated that the virus belonged to the UK SARS-CoV-2 lineage B.1.1.7 (GR 501Y.V1; 20I/S:501Y.V1; Alpha variant).

Keywords

References

  1. Virus Evol. 2020 Apr 10;6(1):veaa027 [PMID: 32296544]
  2. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166 [PMID: 34437519]
  3. N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
  4. Virology. 2021 May;557:70-85 [PMID: 33676349]
  5. Innovation (N Y). 2020 Nov 25;1(3):100061 [PMID: 33169119]
  6. Infect Dis (Lond). 2021 Nov;53(11):876-879 [PMID: 34176397]
  7. Clin Chim Acta. 2021 Jul;518:9-16 [PMID: 33741357]
  8. Clin Microbiol Infect. 2021 Jul 7;: [PMID: 34245907]
  9. J Infect. 2020 Sep;81(3):357-371 [PMID: 32615199]
  10. Emerg Infect Dis. 2020 Jul;26(7):1478-1488 [PMID: 32267220]
  11. Nature. 2021 May;593(7857):136-141 [PMID: 33706364]
  12. N Engl J Med. 2020 Dec 31;383(27):2603-2615 [PMID: 33301246]
  13. N Engl J Med. 2021 Oct 7;385(15):1393-1400 [PMID: 34525275]
  14. Cell Res. 2021 Jun;31(6):720-722 [PMID: 33893398]
  15. Cell. 2020 Nov 12;183(4):1024-1042.e21 [PMID: 32991844]
  16. N Engl J Med. 2021 May 6;384(18):1774-1775 [PMID: 33755376]

Grants

  1. DS8/2021 & DS12/2021/This work was financed by internal funding from the National Medicines Institute

Word Cloud

Created with Highcharts 10.0.0COVID-19viralinfectionvirusSARS-CoV-2vaccinatedwomanhighload1V1introductioneffectivevaccinesexpectedpreventHoweversporadiccasespersonsreporteddescribecasedouble-dosestagesobservedidentificationstartcomingviraemiafinallydetectionDespitedemonstratedmildsymptomsmanifestedsorethroatantibodyresultsshowedproducedpost-infectiouspost-vaccinationimmuneresponsesPhylogeneticanalysisobtainedgenomesequenceindicatedbelongedUKlineageB7GR501Y20I/S:501YAlphavariantCaseReportFullVaccination:ViralLoadsAnti-SARS-CoV-2Antibodiesanti-SARS-CoV-2antibodiesmRNAvaccineloads

Similar Articles

Cited By